Pharmaceutical company Cipla is open to expanding its manufacturing footprint in the US, a move that can relatively de-risk ...

Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

Nomura recommends Buy for Dr. Reddy’s, Cipla, Lupin, Zydus amid pharma stock pressure. Check latest market trends!

Maruti and Cipla trade below long-term P/E averages. Both show solid fundamentals, but growth has slowed. Execution on new ...

New Delhi: Through a recent revised drug alert, the Central Drugs Standard Control Organization (CDSCO) has classified a ...

Nomura India maintained its 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. Cipla anticipates launching its gAbraxane product in 1HFY26 following USFDA approval.

For the year ending March 2024, Cipla reported a 46.5% increase in net profit, reaching Rs 41,553 million, compared to Rs 28,355 million during FY23. The company’s revenue grew by 13.3% to Rs 257,741 ...

New Delhi: The pharmaceutical major Cipla has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) for conducting Phase III ...

The US president vows "major" tariffs on imported medicines - raising fears of an increase in costs for Americans.

US President Donald Trump has stated that the country is set to announce “major tariffs” on pharmaceutical imports very soon.

JB Chemicals & Pharmaceutical marked a growth of 17.1% YoY, while Cipla Ltd saw sales grow 16.3% YoY. Ipca Laboratories on the other hand marked a growth of 14.3% YoY. All these firms recorded ...

The American Lung Association in New York is proud to welcome Cipla back as the lead sponsor of the 2025 LUNG FORCE Walk New York City. As this year’s Breathe Free Sponsor, Cipla continues its ...